Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Humacyte, Inc. on June 9, 2022. The filing details the voting results for two proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance events and voting outcomes rather than financial performance.
Material Changes
No material financial changes are reported in this filing. The primary event is the successful ratification of the board of directors and the independent auditor.
Outlook, Risks, and Unusual Items
The filing contains no management commentary regarding future guidance, risks, or contingencies. It confirms that PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Important Facts for Investors
- Meeting Date: June 9, 2022.
- Quorum: 61,199,997 shares (approximately 59.4% of outstanding shares) were present, establishing a quorum.
- Director Election: All three Class I nominees (Brady W. Dougan, Diane Seimetz, and Max Wallace) were elected to serve until the 2025 annual meeting.
- Auditor Ratification: The appointment of PricewaterhouseCoopers LLP was approved with 61,085,817 votes for, 53,838 against, and 60,342 abstentions.
- Outstanding Shares: As of the April 18, 2022 record date, there were 103,004,572 shares of common stock outstanding.